Patents Examined by San-ming Hui
  • Method for treating gefitinib-resistant non-small-cell lung cancer
    Patent number: 9597299
    Abstract: The present invention relates to a method for treating gefitinib-resistant non-small-cell lung cancer (NSCLC) comprising administering an effective amount of a resveratrol analog, (Z)3,4,5,4?-tetramethoxystilbene (TMS), to a subject in need thereof. The present invention also relates to a method for inducing apoptosis in gefitinib-resistant NSCLC cells comprising contacting the resveratrol analog to the cells at an effective amount. The present methods are mediated by different signaling pathways connected to cell proliferation and differentiation such as mTOR, JNK, and certain EGFR phosphorylated tyrosine kinase.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 21, 2017
    Assignee: Macau University of Science and Technology
    Inventors: Lai-Han Leung, Xing-Xing Fan, Liang Liu, Zebo Jiang
  • Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
    Patent number: 9598447
    Abstract: The disclosure relates to Phosphorus-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the dashed line, A, B, Q, R1, R2, R3, R4, Y1, Z, and a are as defined herein, compositions comprising an effective amount of a Phosphorus-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Phosphorus-Substituted Quinoxaline-Type Piperidine Compound.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: March 21, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Dawit Tadesse, Laykea Tafesse, Xiaoming Zhou
  • Very low-dosed solid oral dosage forms for HRT
    Patent number: 9592245
    Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 14, 2017
    Assignee: Bayer Intellectual Property GMBH
    Inventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
  • Compositions and methods for improving lactation
    Patent number: 9585870
    Abstract: The present disclosure relates to the use of pharmaceutical agents to manipulate serotonin in animal mammary glands. Use of the serotonin agents results in increased PTHrP levels, resulting in the release of calcium from the bone, which improves lactation.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 7, 2017
    Assignees: UNIVERSITY OF CINCINNATI, WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Nelson Horseman, Laura Hernandez Baumgard
  • Lactams
    Patent number: 9586901
    Abstract: Lactams of formulae (I) and (II) and their use in the treatment of microbial infections and microbial contamination of surfaces, particularly infections and surface contaminations characterized by biofilm formation. Compounds of formula (I) and (II) substituted with acrylate or methacrylate groups and their attachment to surfaces or polymers to inhibit microbial contamination are also provided.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: March 7, 2017
    Assignee: UNILEVER PLC
    Inventors: Naresh Kumar, George Iskander
  • Derivatives of 6-substituted triazolopyridazines as Rev-Erb agonists
    Patent number: 9586963
    Abstract: The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: March 7, 2017
    Assignee: Genfit
    Inventors: Maryline Bourotte, Jean-Francois Delhomel, Mathieu Dubernet, Marie-Helene Gouy
  • Estrogen receptor ligands
    Patent number: 9586891
    Abstract: Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R1 to R9 have meanings as defined in the Specification, are useful as estrogen receptor ligands.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: March 7, 2017
    Assignee: Karo Pharma AB
    Inventors: Aiping Cheng, Neeraj Garg, Lars Krüger, Joakim Löfstedt, Eva Koch, Konrad Koehler, Lars Hagberg, Daniel Nöteberg
  • System and method for alleviating the appearance of scars and/or scar tissue
    Patent number: 9579388
    Abstract: A system for alleviating the appearance of scar tissue, said system comprising a combination of two compounds; a first compound having properties that perform skin regeneration; and a second compound having properties that provide a physical barrier adapted to protect scar tissue by insulating it from ambient air while maintaining and protecting said first compound that is combined therewith.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: February 28, 2017
    Inventors: Rene Gauthier, Claude Marquis
  • Process to prepare surface-modified mineral material, resulting products and uses thereof
    Patent number: 9580605
    Abstract: The present invention refers to a process to modify at least part of the surface of at least one mineral material, and to the use, as an additive in an aqueous suspension of mineral materials having a pH between 5 and 10, of at least one agent, wherein the additive allows for the formation of a low volume, high solids content filter or centrifuge cake on dewatering the suspension.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: February 28, 2017
    Assignee: Omya International AG
    Inventors: Guenter Wimmer, Joachim Schölkopf, Hans-Joachim Weitzel, Fridolin Stauffer
  • Therapeutic compounds
    Patent number: 9573906
    Abstract: The invention provides compounds of formulae (I), (II), (III), and (IV): and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: February 21, 2017
    Assignee: Arizona Board of Regents, A Body Corporate of the State of Arizona Acting for and on behalf of Arizona State University
    Inventors: Carl E. Wagner, Peter W. Jurutka, Pamela A. Marshall
  • Vortioxetine salt and crystal thereof, their preparation method, pharmaceutical compositions and usage
    Patent number: 9562024
    Abstract: The present invention relates to the novel vortioxetine salts, solvates and crystalline forms thereof, specifically, vortioxetine hemihydrobromide and a crystalline form thereof, and isopropanol solvate of vortioxetine hydrobromide and a crystalline form thereof. Compared to the known vortioxetine hydrobromide, the vortioxetine salts, solvates and crystalline forms of the present invention have improved features in stability, hygroscopicity and purity. The present invention also relates to preparation methods of the vortioxetine salts, solvates and crystalline forms, pharmaceutical compositions thereof and their uses in the manufacture of antidepressant drugs.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 7, 2017
    Assignee: HANGZHOU PUSHAI PHARMACEUTICAL TECHNOLOGY CO., LTD
    Inventors: Xiaoye Song, Xiaoxia Sheng, Xiaohong Sheng
  • Synergistic combinations of organic acid useful for controlling microoganisms in industrial processes
    Patent number: 9555018
    Abstract: The present invention provides a method of controlling bacterial contamination using synergistic interactions of antimicrobials. The invention utilizes a combination of organic acids where the combined antimicrobial effect is synergistic.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 31, 2017
    Assignee: Solenis Technologies, L.P.
    Inventors: Corinne E. Consalo, John S. Chapman
  • Composition in form of a gel for the virucidal disinfection of mammalian skin
    Patent number: 9554994
    Abstract: The present invention describes a composition in form of a gel for the virucidal disinfection of mammalian skin comprising 71 to 95 weight percent of a C1 to C3 monoalcohol, 0.01 to 1 weight percent thickener and wherein the composition has a viscosity range of from 3000 to 19000 mPas measured at 20° C. with spindle LV3 at a speed of 2.5 rpm. Furthermore, the invention describes a method for virucidal disinfection of skin.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: January 31, 2017
    Assignee: Ecolab USA Inc.
    Inventors: Laurence Geret, Bernhard Meyer, Stefan Jäger
  • Modified release doxycycline composition
    Patent number: 9532996
    Abstract: Doxycycline formulations with a reduced food effect are disclosed. Particularly disclosed are modified release formulations which can be administered once a day and exhibit a reduced food effect. Methods of treating inflammatory conductions such as rosacea or inflammatory symptoms such as the papules and pustules of rosacea or acne vulgaris are also disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: January 3, 2017
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Ankit Baheti, Bijay Kumar Padhi, Rajeev Singh Raghuvanshi
  • Controlled release formulations of levodopa and uses thereof
    Patent number: 9533046
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 3, 2017
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim Kou, Laman Alani
  • Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules
    Patent number: 9532947
    Abstract: A formulation for oral transmucosal administration of at least one active principle with antispasmodic and/or analgesic effect, including the active principle in base form and/or in salt form, an aqueous alcohol solution titrating at least 35° alcohol by weight, the active principle being present in a state of stable and complete dissolution in the aqueous alcohol solution. Also, a method of preparing this formulation and its use for treating spastic crises.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: January 3, 2017
    Inventors: Philippe Perovitch, Marc Maury
  • Synergistic combination of a lenacil compound and terbutryn for dry film protection
    Patent number: 9526248
    Abstract: A synergistic antimicrobial composition containing lenacil and terbutryn is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: December 27, 2016
    Assignees: ROHM AND HAAS COMPANY, DOW GLOBAL TECHNOLOGIES LLC
    Inventors: Kenneth M. Donnelly, Pierre Marie Alain Lenoir, Lukas Thomas Johannes Villiger
  • Dosing regimen for Janus Kinase (JAK) inhibitors
    Patent number: 9522151
    Abstract: The present invention provides a method for treating allergic dermatitis, atopic dermatitis, or one or more symptoms thereof in a mammal in need, which method comprises administering to the mammal a first therapeutically effective dose of a Janus Kinase (JAK) inhibitor twice a day for a number of days sufficient to ease or eliminate one or more clinical signs in the mammal, followed by a second therapeutically effective dose of the JAK inhibitor at a reduced frequency.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: December 20, 2016
    Assignee: Zoetis Services LLC
    Inventors: Andrea J. Gonzales, Sallie B. Cosgrove, Phyllis B. Malpas, Michael Rolf Stegemann, Wendy Turner Collard
  • Histone deacetylase 6 selective inhibitors for the treatment of bone disease
    Patent number: 9512083
    Abstract: This invention relates to methods for treating bone disease associated with osteoclast activation using HDAC6 selective inhibitors, e.g., small molecule inhibitors such as reverse amide compounds.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 6, 2016
    Assignee: The General Hospital Corporation
    Inventors: Noopur Raje, Loredana Santo
  • Methods for the treatment of fibromyalgia and chronic fatigue syndrome
    Patent number: 9511079
    Abstract: The invention relates to methods for the treatment of fibromyalgia and chronic fatigue syndrome by administration of a transdermally applied androgen composition. The treatment is both safe and effective for treating fibromyalgia-related pain and fatigue, as well as chronic fatigue syndrome.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: December 6, 2016
    Assignee: White Mountain Pharma, Inc.
    Inventors: Hillary D. White, Robert Gyurik